A CD40L-targeting protein reduces autoantibodies and improves disease activity in patients with autoimmunity
Jodi L. Karnell(Integrated BioTherapeutics (United States)), Jörn Drappa(Integrated BioTherapeutics (United States)), Manuel Baca(Tri-Institutional Therapeutics Discovery Institute), Rachel Moate, Ximing Xiong, Isharat Yusuf(Gossamer Bio (United States)), Stacey Drabic, M. Albulescu(AstraZeneca (United Kingdom)), Vaheh Oganesyan, Steven Eck, Thomas Thisted, Rachel Ettinger(AstraZeneca (Australia)), Katie Streicher(AstraZeneca (United States)), Michele Gunsior(Integrated BioTherapeutics (United States)), Jing Li(City Of Hope National Medical Center), Yan Li(Shanghai Jiao Tong University), Ronald Herbst(Unknown), Melissa de los Reyes, David Howe, Ulf Müller‐Ladner(Justus-Liebig-Universität Gießen), Liangwei Wang(Colorado State University)
Cited by 98
Related Papers
Genome sequencing in microfabricated high-density picolitre reactors
|Nature|2005|7.7k
Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial
|The Lancet|2019|722
The conserved SOCS box motif in suppressors of cytokine signaling binds to elongins B and C and may couple bound proteins to proteasomal degradation
|Proceedings of the National Academy of Sciences|1999|632
IL-21 drives expansion and plasma cell differentiation of autoreactive CD11chiT-bet+ B cells in SLE
|Nature Communications|2018|563
Suppressor of cytokine signaling-3 preferentially binds to the SHP-2-binding site on the shared cytokine receptor subunit gp130
|Proceedings of the National Academy of Sciences|2000|465